Institutional members access full text with Ovid®

Share this article on:

Levosimendan – an inoprotective drug or much ado about nothing?*

Lehmann, Andreas MD; Radke, Joachim MD; Sack, Falk-Udo MD

doi: 10.1097/CCM.0b013e3182266179

Department of Anaesthesiology and Intensive Care Medicine; Department of Cardiac Surgery; Klinikum der Stadt Ludwigshafen; Ludwigshafen, Germany

Dr. Lehmann was consultant on levosimendan for Orion Pharma, Germany, took part in advisory board meetings on levosimendan, and gave paid lectures on levosimendan. He was paid by Orion Pharma, Germany, and Abbott, Germany. The remaining authors have not disclosed any potential conflicts of interest.

© 2011 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins